Literature DB >> 6732768

Gangliosides of normal and neoplastic human melanocytes.

J M Carubia, R K Yu, L J Macala, J M Kirkwood, J M Varga.   

Abstract

The major ganglioside component isolated from diploid human melanocytes is sialosyllactosylceramide (GM3 86-91% of total sialic acid). The corresponding disialo derivative (GD3) is found as a minor component (2-6% of total sialic acid) in the membranes of these cells. In human melanoma cells, grown in tissue culture, GD3 is the predominant ganglioside component (48-63% of total sialic acid). Withdrawal of TPA from the culture medium of normal melanocytes or addition of TPA to the medium of melanoma cells had no significant effect on GM3/GD3 ratios. We conclude that the difference between the composition of gangliosides is related to the normal vs transformed phenotypes of melanocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732768     DOI: 10.1016/0006-291x(84)91282-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  GD3 expression in CHO-K1 cells increases growth rate, induces morphological changes, and affects cell-substrate interactions.

Authors:  Jose L Daniotti; Adolfo R Zurita; Vera M T Trindade; Hugo J F Maccioni
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

Review 2.  Biosynthesis and functions of gangliosides: recent advances.

Authors:  K O Lloyd; K Furukawa
Journal:  Glycoconj J       Date:  1998-07       Impact factor: 2.916

3.  Multiplex RT-PCR method for the analysis of the expression of human sialyltransferases: application to breast cancer cells.

Authors:  M A Recchi; A Harduin-Lepers; Y Boilly-Marer; A Verbert; P Delannoy
Journal:  Glycoconj J       Date:  1998-01       Impact factor: 2.916

4.  Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.

Authors:  Konstantin Dobrenkov; Irina Ostrovnaya; Jessie Gu; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2016-06-15       Impact factor: 3.167

5.  Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells.

Authors:  Kazunori Hamamura; Keiko Furukawa; Takanori Hayashi; Takeshi Hattori; Junji Nakano; Hideyuki Nakashima; Tetsuya Okuda; Hideki Mizutani; Hisashi Hattori; Minoru Ueda; Takeshi Urano; Kenneth O Lloyd; Koichi Furukawa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-22       Impact factor: 11.205

6.  Expression cloning of a CMP-NeuAc:NeuAc alpha 2-3Gal beta 1-4Glc beta 1-1'Cer alpha 2,8-sialyltransferase (GD3 synthase) from human melanoma cells.

Authors:  K Nara; Y Watanabe; K Maruyama; K Kasahara; Y Nagai; Y Sanai
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

7.  Expression of alpha 2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: high level expression in melanomas and up-regulation in activated T lymphocytes.

Authors:  S Yamashiro; M Okada; M Haraguchi; K Furukawa; K O Lloyd; H Shiku; K Furukawa
Journal:  Glycoconj J       Date:  1995-12       Impact factor: 2.916

8.  Site restricted and neuron dominant expression of alpha 2,8sialyltransferase gene in the adult mouse brain and retina.

Authors:  A Yamamoto; S Yamashiro; S Fukumoto; M Haraguchi; M Atsuta; H Shiku; K Furukawa
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

9.  An improved method for the measurement of total lipid-bound sialic acids after cleavage of alpha 2,8 sialic acid linkage with Vibrio cholerae sialidase in the presence of cholic acid, SDS and Ca2+.

Authors:  M A Maliakal; M H Ravindranath; R F Irie; D L Morton
Journal:  Glycoconj J       Date:  1994-04       Impact factor: 2.916

10.  Monoclonal antibody against a lactose epitope of glycosphingolipids binds to melanoma tumour cells.

Authors:  K Ding; T Ekberg; J Zeuthen; S Teneberg; K A Karlsson; A Rosén
Journal:  Glycoconj J       Date:  1993-10       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.